Stryker (NYSE:SYK) Releases FY 2026 Earnings Guidance

Stryker (NYSE:SYK) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 14.900-15.100 for the period, compared to the consensus estimate of 14.950. The company issued revenue guidance of -.

Analyst Ratings Changes

SYK has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. decreased their price objective on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Needham & Company LLC lowered their price target on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday. Jefferies Financial Group reissued a “buy” rating and set a $465.00 price objective on shares of Stryker in a research report on Wednesday, March 4th. Finally, Canaccord Genuity Group reduced their price objective on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a report on Friday. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $403.73.

Stryker Stock Down 6.3%

Shares of SYK traded down $19.70 during mid-day trading on Friday, hitting $295.43. 4,518,113 shares of the company’s stock were exchanged, compared to its average volume of 2,089,251. The company has a market cap of $113.15 billion, a price-to-earnings ratio of 35.17, a P/E/G ratio of 1.84 and a beta of 0.92. Stryker has a fifty-two week low of $294.55 and a fifty-two week high of $404.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The stock’s 50-day moving average is $345.67 and its 200-day moving average is $356.95.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the firm earned $2.84 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, sell-side analysts anticipate that Stryker will post 14.91 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were issued a dividend of $0.88 per share. The ex-dividend date was Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s dividend payout ratio is 41.90%.

Insider Activity

In related news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.60% of the company’s stock.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY‑2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer‑term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near‑term upside expectations and add selling pressure. Article Title

Institutional Trading of Stryker

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC boosted its holdings in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares in the last quarter. Schnieders Capital Management LLC. purchased a new stake in Stryker in the second quarter valued at $205,000. Marshall Wace LLP boosted its stake in Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after acquiring an additional 77,831 shares in the last quarter. Nebula Research & Development LLC acquired a new position in Stryker in the second quarter valued at $219,000. Finally, HUB Investment Partners LLC purchased a new position in shares of Stryker during the second quarter worth about $253,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.